Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy

N Engl J Med. 2019 Jun 13;380(24):2375-2376. doi: 10.1056/NEJMc1903064.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Alemtuzumab / therapeutic use*
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antineoplastic Agents, Immunological / adverse effects*
  • Arrhythmias, Cardiac / chemically induced
  • Female
  • Humans
  • Melanoma / drug therapy
  • Myocarditis / chemically induced
  • Myocarditis / drug therapy*
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors*

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • Programmed Cell Death 1 Receptor
  • Alemtuzumab
  • pembrolizumab